Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib in Advanced NSCLC with EGFR Exon 20 Insertion Mutation
NCT04858958Phase 1Completed
- Sponsor
- Allist Pharmaceuticals
- Start
- Aug 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Allist Pharmaceuticals. Primary endpoint: Objective Response Rate at 12 months. Started Aug 2020; status: completed.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04858958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04858958.